'SII hasn't contracted full production to Centre; states can get vaccines'

In order to expand and liberalise the countrywide vaccination drive, the union government has on April 19 announced the liberalised pricing and accelerated national vaccination strategy

Covishield
BS Web Team
2 min read Last Updated : Apr 22 2021 | 8:09 PM IST
The union government on Thursday clarified that Serum Institute of India (SII) has not contracted all its production of coronavirus vaccine to the Centre till May 25 and that State governments are free to procure vaccine doses from the vaccine manufacturers as per the liberalised pricing and accelerated vaccination strategy.

"There have been some media reports suggesting that Serum has contracted all its production till May 25, 2021 to the Centre, and therefore till that date the State governments will not be able to procure vaccine from SII. These media reports are based on incorrect facts and are without any basis," said the union health ministry in a statement

In order to expand and liberalise the countrywide vaccination drive, the union government has on April 19 announced the liberalised pricing and accelerated national vaccination strategy which would come into effect from May 1.

A key feature of the announcement is that  the “vaccine manufacturers would supply 50 per cent of their monthly Central Drugs Laboratory (CDL) released doses to Govt. of India and would be free to supply remaining 50 per cent doses to State governments and in the other than Central government channel”. 

"The state governments are free to purchase the vaccine doses from the vaccine manufacturers," said the health ministry.

Therefore, it is very clear that every month out of the total CDL cleared doses available with any vaccine manufacturer, 50 per cent doses would be available for other than Central government channels.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :CoronavirusCoronavirus TestsCoronavirus Vaccine

Next Story